Cerebrolysin

Educational overview

Not FDA-approved; it is an animal-derived peptide mixture rather than one defined peptide, and evidence for neurorecovery remains uncertain.

Cerebrolysin is a porcine brain-derived peptide preparation produced by standardised enzymatic breakdown of lipid-free pig brain proteins. It is a mixture rather than a single defined molecule, consisting of roughly eighty percent low-molecular-weight peptides and twenty percent free amino acids, and is manufactured in Austria by EVER Pharma, formerly EBEWE. It is classed as a neurotrophic or neuropeptide preparation, and its proponents describe pharmacodynamic properties resembling endogenous growth factors such as nerve growth factor and BDNF, with anti-apoptotic, anti-oxidative, and synaptic-plasticity effects in cell and animal models. It is administered by intravenous infusion or intramuscular injection in the countries where it is licensed.

The clinical evidence comes mainly from Russia, Eastern Europe, Austria, and Asia, and much of it is manufacturer-sponsored. Randomised trials have been conducted in acute ischaemic stroke, vascular and Alzheimer dementia, and traumatic brain injury. The Cochrane review by Ziganshina and colleagues, most recently updated in 2020 and again in 2023, found moderate-quality evidence that Cerebrolysin probably has little or no effect on all-cause death in acute ischaemic stroke and a possible increase in non-fatal serious adverse events. A separate Cochrane review in vascular dementia found low-quality evidence of modest cognitive benefit. Independent replication outside the sponsoring regions is limited, and the large CASTA trial did not show benefit over placebo.

Cerebrolysin is registered as a prescription medicine in Austria, Russia, China, South Korea, and several dozen other countries, mostly for stroke, dementia, and brain injury, but it has no marketing authorisation from the FDA, the EMA, the MHRA, or the TGA. In the United States it is an unapproved new drug, and in 2021 the FDA issued a warning letter to a clinic marketing it. Because it is an animal-derived biological mixture, it cannot be characterised or compounded in the way a single synthetic peptide can, and products offered online outside the licensed supply chain have no assurance of origin, sterility, or identity. Import and possession rules vary by jurisdiction.

Where it is licensed, Cerebrolysin is supplied as a sterile solution in single-use glass ampoules or vials, and the manufacturer label sets out storage below room temperature limits, protection from light, and disposal of any discoloured or opened remainder. Product sourced outside that chain carries no verified storage history. Because the preparation is given by injection or infusion, the relevant records are the route, volume, lot number, expiry date, and the source of supply. A dose log that captures these details, together with an inventory record of ampoules on hand and their expiry dates, provides the traceability that would otherwise depend on a pharmacy dispensing record.

Category

Unapproved peptide mixture / nootropic

Routes represented

Other / unspecified

Storage context

Follow the product or pharmacy label; requirements vary by route and formulation.